Related Experiment Video

Updated: Jun 3, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the

Shanu Modi1

  • 1Memorial Sloan Kettering Cancer Center, New York, United States.

Future Oncology (London, England)
|January 9, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.5K
High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

1.9K

Related Experiment Videos

Last Updated: Jun 3, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.5K
High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

1.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

Articles linked to this work by shared authors, journal, and citation graph.

CDKPredict: a clinicogenomic model for risk-adapted therapeutic intervention in breast cancer.

Research square·2026

ERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-non-amplified Metastatic Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study.

Clinical breast cancer·2026

New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice.

Breast (Edinburgh, Scotland)·2026

Real-world treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States.

Breast (Edinburgh, Scotland)·2026

First-line osimertinib with or without chemotherapy for EGFR-mutant advanced NSCLC in China: a cost-effectiveness analysis.

Future oncology (London, England)·2026

TroFuse-032 study design: pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy as neoadjuvant therapy for early-stage, triple-negative breast cancer or HR-low+/HER2- breast cancer.

Future oncology (London, England)·2026

Interleukin-6 as a prognostic biomarker in repatocellular carcinoma treated with systemic therapy: a systematic review and meta-analysis.

Future oncology (London, England)·2026

Patient experiences and unmet needs in diagnosis and treatment of metastatic colorectal cancer: results of a US survey.

Future oncology (London, England)·2026

Evaluating taletrectinib in the treatment of patients with ROS1 fusion-positive non-small cell lung cancer.

Future oncology (London, England)·2026

Tissue-based PEG10 expression as an exploratory biomarker associated with first-line R-CHOP treatment outcome in diffuse large B-cell lymphoma.

Future oncology (London, England)·2026

Mild Moxibustion Alleviates Primary Dysmenorrhea in Rats Through TRPV1-Associated Modulation of NF-κB Signaling and Uterine Oxidative Stress.

Journal of pain research·2026

Beyond the Individual: An Ecological Analysis of Workplace Bullying in Aotearoa New Zealand Midwifery.

Journal of nursing management·2026

Potential clinical significance of soluble and extracellular vesicle-bound HER2 in breast cancer.

Nanomedicine : nanotechnology, biology, and medicine·2026

"I'm much more ok with my body just being mine and treating it well": women's experiences of empowerment after completing a holistic health programme.

Psychology & health·2026

Effect of ultrasound-guided visual biofeedback performed by midwives on duration of second stage of labor: randomized controlled trial.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2026

Multiple Recurarization Episodes After Sugammadex Reversal in Hyperthermic Intraperitoneal Chemotherapy: A Case Report.

A&A practice·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us